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OPTIMAL DURATION OF INTRAPARTUM ANTIBIOTIC PROPHYLAXIS FOR GROUP B
STREPTOCOCCUS AND EFFECTS ON PRACTICE PATTERNS. Emma L Barber, Edmund F Funai,
MD, Michael B Bracken, PhD, MPH, Guomao Zhao, BS, Irina A Buhimschi, MD, and Jessica L Illuzzi.
Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine,
New Haven, CT, United States.
The 2002 CDC guidelines recommend a minimum of four hours of intrapartum penicillin G prophylaxis to assure a
neonate is adequately prophylaxed against group B streptococcus (GBS). We examined the validity of this duration
through the relationship between duration of prophylaxis and fetal serum penicillin G levels among fetuses exposed
to less than 4 hours of prophylaxis compared to longer durations. We also investigated if clinicians were altering
management to achieve four hours of prophylaxis.

Ninety-eight laboring GBS positive women carrying singleton gestations >37 weeks received penicillin G according
to the CDC protocol. Umbilical cord blood samples were collected at delivery and penicillin G levels measured by
high-performance liquid chromatography. Intra and inter-assay coefficient of variation were <3%. Seventy of 96
eligible clinicians (72.9%) completed our survey.

Fetuses exposed to less than 4 hours prophylaxis had higher penicillin G levels than those exposed to greater than 4
hours (p=0.003). In multivariable linear regression analysis, fetal penicillin G levels were determined by time of
exposure, time since last dose, dosage, and number of doses, but not maternal BMI. Penicillin G levels increased
linearly until 1 hour (R2=.40) and then decreased rapidly according to a power-decay model (R2=.67). All subgroups analyzed were above the minimum inhibitory concentration (MIC) for GBS (0.1μg/mL)(p<0.002).
Individual samples were 10-179 fold above the MIC. In our survey, only 22.9% of clinicians reported not altering
their management of labor in GBS positive pregnancies that achieved less than 4 hours of prophylaxis. These
alterations included “laboring down” or delaying pushing; turning off or decrease an oxytocin infusion; or delaying
or avoiding artificial rupture of membranes.

Short durations of prophylaxis achieved levels significantly above the MIC, suggesting a benefit even in precipitous
labors. The designation of infants exposed to less than 4 hours of prophylaxis as particularly at risk for GBS sepsis
may be pharmacokinetically inaccurate. However, clinicians report delaying labor to achieve four hours. The 2002
CDC guidelines are being interpreted differently in the clinical setting than the authors may have intended. The
effects and consequences of this interpretation are unknown.
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1
INTRODUCTION
Group B Streptococcus: the organism and its pathology
Group B streptococcus also known as streptococcus agalactiae, is a gram-positive betahemolytic diplococcus that occurs in both pairs and chains. The name agalactiae means
“without milk” as group B streptococcus was originally isolated from the breast of a cow
and was thought to be a pathogen that only affected domesticated cattle causing mastitis.

The main virulence factor of group B streptococcus is its polysaccharide capsule. The
capsule prevents the deposition of complement on the surface of the organism unless a
specific antibody is present. These polysaccharides are made up of approximately 150
repeating oligosaccharide subunits.1 The organism is further classified into 9 different
serotypes based upon the different immunologic reactivity of its various capsules. The
nine capsular serotypes differ in the arrangements of monosaccharides within the
oligosaccharide-repeating units. Each of the oligosaccharide-repeating units ends in a
sialic moiety. The sialic acid moiety, made up of N-acetylneuraminic acid, is the crucial
portion of the capsule, which prevents the complement deposition. Through molecular
mimicry, the sialic acid moiety prevents the human immune system from recognizing the
organism. Presence of an antibody specific to the capsular polysaccharide has been
shown to be sufficient to prevent invasive disease.2

Additional virulence factors of group B streptococcus allow it to invade into the host
tissues and cells. For example, the invasion-associated gene (iagA) encodes a
glycosyltransferase.3 This glycosyltransferase produces a cell membrane anchor for
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lipoteichoic acid and allows the bacteria to invade into the blood-brain barrier. A second
virulence factor is alpha protein C. It is a protein on the surface of group B
streptococcus, which binds to the host glycosaminoglycans and also promotes invasion.4
Additionally, pilins present in group B streptococcus function as adhesins, which
promote entry of group B streptococcus into the central nervous system.5 A fourth factor
is a C5a peptidase enzyme which cleaves the complement protein C5a when it is
deposited on the organism‟s surface. This prevents formation of the membraneassociated complex that is necessary for host immune system mediated killing of the
organism.6

Group B streptococcus was originally described by Rebecca Lancefield in 1933 and carries the
designation “group B” as it carries the B Lancefield antigen. In 1935, Lancefield described the
first association of group B streptococcus in humans when she recorded the asymptomatic
carriage of group B streptococcus in the vagina. Since that time, the organism has been found to
be present in an asymptomatic carrier state in the vagina, urethra, rectum and other areas of the
gastrointestinal tract. It can also cause symptomatic infection in non-pregnant adults in the form
or urinary tract infections or in immunocompromised patients or patients with chronic disease, it
can cause sepsis, cellulitis and pneumonia. The case fatality rate for these adult group B
streptococcal infections is 15-32%.7, 8 In pregnant patients, group B streptococcus causes urinary
tract infection, amnionitis, endometritis, wound infection, and more rarely, maternal sepsis or
meningitis.9-13 Urinary tract infections with group B streptococcus are present in 2-4% of all
pregnancies.14, 15
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Although the organism can cause morbidity and mortality in adult populations it has been most
noted for its pathogenic effects in neonates. Eickhoff described the first case of neonatal group
B streptococcal sepsis in 1964 and since that time, group B streptococcus has been recognized as
the leading cause of neonatal sepsis.16-18 It is also a major cause of neonatal pneumonia, and
meningitis.19 Neonatal group B streptococcal sepsis has been divided into two categories, earlyonset disease and late-onset disease. Early-onset disease is responsible for 80% of the total of
neonatal group B streptococcal infections. Early-onset disease, by definition, occurs in the first 7
days of life. Furthermore, in 90% of cases, symptoms and disease presentation occur in the first
24 hours of life. Early-onset disease presents as pneumonia or respiratory symptoms in 54% of
neonates; as sepsis without focus in 27% of neonates; and as meningitis in 15% of neonates.20 In
contrast, late onset disease is defined as disease that occurs at greater than 1 week of life and
before 3 months of life. Late onset disease presents as sepsis in 46% of neonates and as
meningitis in 37% of neonates.

In various studies, group B streptococcus has been found to colonize the vagina and rectum in
anywhere from 1.2% to 35% of pregnant women;20 a range of 10-30% is the figure most often
quoted in the literature.9, 16, 21-24 Data from colonization studies is present dating back to 1980.
These studies have been performed in many geographic areas, including Africa, Asia, Europe,
the Americas and the Middle East. Colonization rates vary in different cultural contexts,
communities, and across national boundaries. Previously, the rates of group B streptococcus
colonization were less in developing countries, but there is new evidence that rates of
colonization in the developing world are catching up to rates in the developed world.25 The
reasons for this increase are hypothesized to do with increasing contact of individuals in a
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population with one another and the increased propensity for spread of bacteria that results from
such contact.

Maternal colonization with group B streptococcus is identified by using swabs to sample the
maternal rectum, vagina, and perineum. These swabs are placed in culture media and the isolates
present are allowed to grow to determine if group B streptococcus is present. Rapid antigen
testing is an alternative method of detection, but, is limited by a lower sensitivity.26 Recently, the
use of polymerase chain reaction (PCR) and optical immunoassay have been proposed as
alternative “rapid” techniques which could be used to evaluate women while they are in labor
rather than using cultures which must be taken during prenatal visits in the weeks before labor.27,
28

The ability to detect organism at the time of delivery is especially important as women may be

colonized transiently and may be culture negative in the weeks before delivery, but culture
positive at the crucial time of birth.

As mentioned previously, the presence of group B streptococcus in the mother is most often as
an asymptomatic carrier state; however, transmission to the child can cause significant neonatal
morbidity and mortality. The mechanism of this transmission is either: (1) transmission to the
fetus in utero; or (2) transmission to the fetus during descent through a birth canal infected with
group B streptococcus. In the first mechanism, intrauterine infection of the fetus occurs as a
result of the organism ascending into the amniotic fluid compartment, often in the setting of
ruptured membranes, and proliferating there. Fetal aspiration of group B streptococcus infected
amniotic fluid can result in pneumonia and sepsis. The fetus can also be exposed to the organism
during passage through the vaginal canal. Passage through a group B streptococcus infected
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vaginal canal causes the infant to be colonized by the organism on the skin and mucous
membranes; however, the transmission of group B streptococcus from a colonized mother to her
neonate is not universal. Once the organism is present on the neonatal mucous membranes or
neonatal respiratory epithelium, it must invade these structures. Proteins on the surface of the
organism such as alpha-C proteins, the Rib protein, fibrinogen binding protein A and a C5a
peptidase are crucial for the attachment of the organism to the epithelium and extracellular
matrix and the organism‟s intracellular invasion of host cells.29

Data on the rates of neonatal colonization after birth varies in different studies from 35% to 69%
and the figure is often reported to be approximately 50%.30, 31 However, only 1-2% of infants
born to mothers with group B streptococcal colonization develop early onset group B
streptococcal disease.32 Once the neonate has group B streptococcal disease, the case fatality rate
is estimated to be 4% for all neonates22 and 6% among premature neonates.33 Data from the
1970s suggested a higher case fatality rate of 15-50%, but due to improved neonatal care the case
fatality rate has been steadily decreasing.16 Neonatal infection also has neurologic sequelae in
10-20% of cases.9, 22 Sequelae can include long term hearing loss, blindness and developmental
delay.22

There are numerous risk factors associated with early-onset invasive neonatal group B
streptococcal disease. They include: maternal bacteriuria during pregnancy9, maternal urinary
tract infection34, maternal fever34, preterm delivery (less than 37 weeks),35 post-date delivery
(greater than 42 weeks)36, rupture of membranes greater than 12 hours before delivery37,
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previous miscarriage38, previous infant born with invasive group B streptococcal disease9, black
race38, teenage mother38, and gestational diabetes39.

As discussed previously, the first case of group B streptococcal neonatal sepsis was identified in
1964.40 In the 1970s, there were 2-3 cases of group B streptococcal sepsis per 1,000 live births.41
These rates were higher than the rates of congenital syphilis, rubella and herpes, all diseases for
which routine screening and treatment strategies had been designed and implemented. As a
result, various strategies were pursued to attempt to decrease the transmission of group B
streptococcus to neonates and decrease the disease incidence. Initially, attempts were made to
treat mothers with antibiotics in an attempt to eradicate group B streptococcus from the maternal
reservoir. In one study, pregnant women colonized with group B streptococcus were given oral
antibiotics for 1 week during the third trimester. Upon presentation to the labor floor, 30% were
colonized at the time of delivery and there was no difference in colonization rates between the
group treated with antibiotics and those women who were not treated.42

A second study treated

pregnant women with a 14-day long course of antibiotic treatment in the third trimester and also
treated their sexual partners to eliminate a possible source of re-infection. Seventy percent of
those women were colonized three weeks following this treatment.43 From these two studies it
was concluded that it was not possible to eradicate group B streptococcus in the maternal
gastrointestinal tract and vagina through use of intermittent antibiotic treatment and focus shifted
to other methods of treatment, namely, intrapartum antibiotic prophylaxis.

7
History of Public Policy and Research Surrounding Intrapartum Prophylaxis
The idea of intrapartum antibiotic prophylaxis to treat group B streptococcus was first suggested
in 1976 by Ablow.44 The aims of intrapartum prophylaxis are: (1) to decrease colony counts
throughout the birth canal at the time of delivery; (2) to prevent the organism from ascending and
proliferating in the amniotic fluid compartment; and (3) to achieve adequate levels of effective
antibiotic in the fetal bloodstream during labor.45 Two non-randomized studies conducted in the
late 1970s and early 1980s offered support for intrapartum prophylaxis by showing that neonatal
colonization with group B streptococcus was decreased through the use of intravenous ampicillin
given to the mother at the time of delivery. Although these studies were underpowered to show
statistical significance, they did report a reduction in early-onset invasive group B streptococcal
disease in those neonates born to mothers treated with ampicillin.46, 47

The first randomized trial to examine the question of intrapartum prophylaxis as a preventative
measure for group B streptococcal disease was Boyer et al performed in 1986.48 They studied a
group of women whom they considered to be at a higher risk for having a child with group B
streptococcal disease. Enrollment in the study required the patient to have a positive group B
streptococcus culture recorded during prenatal care and to have the presence of a risk factor.
Risk factors were either preterm labor (< 37 weeks gestation) or prolonged rupture of membranes
(> 12 hours prior to presentation to the labor floor). Women with fever (>37.5 degrees Celsius)
were excluded from the study as they could not be randomized to the control treatment (no drug)
and all were given ampicillin. The rationale behind selection of this higher risk population was
that the incidence of early-onset group B streptococcal disease among infants born to these
mothers was 41 per 1,000 births as compared with the 2-3 cases per 1,000 births among mothers
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in the general population. Additionally, neonates born to mothers with these risk factors
represented 62% of cases of early onset disease and 94% of all case fatalities at the authors‟
institution. These women with risk factors and positive cultures were randomized to received
intrapartum ampicillin or no antibiotic treatment. Of note, the neonates in the intrapartum
ampicillin group also received 4 doses of intramuscular ampicillin at 12 hours intervals
following delivery. The outcomes evaluated by the study were neonatal colonization as
measured by cultures taken at birth from 5 external sites on the neonate (external auditory canal,
stomach contents obtained by nasogastric aspiration, throat, umbilicus and rectum) and neonatal
bacteremia. The results showed that neonatal colonization was statistically significantly lower
(p<0.001) in the ampicillin group (8/85 neonates, 9%) compared with the control group (40/79
neonates, 51%). Colonization at multiple sites (defined as 3 or greater sites) was also lower in
the ampicillin group (3/85, 4% vs. 24/79, 30%; p<0.001). Bacteremia was present in 0/85 (0%)
of the ampicillin treated infants and 5/79 (6%) of the control group infants (p=0.024). The paper
concluded that “intrapartum ampicillin prophylaxis in women with positive prenatal cultures for
group B streptococcus who have certain perinatal risk factors can prevent early-onset neonatal
group B streptococcal disease”.48 This paper was the seminal work on intrapartum prophylaxis
for prevention of group B streptococcal disease and became the foundation for future clinical
recommendations.

Certain aspects of Boyer et al warrant mention. First, in a study in which carriage of an
organism known to cause infection in the fetus via amniotic fluid infection, the authors elected to
exclude women with fever. Fever is one of the risk factors for group B streptococcal disease and
in analysis has been shown to be the risk factor with the largest relative risk for developing early
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onset disease.49 These women with fever represented 13 women in the study. Second, the
authors stopped enrollment in the study once their results had achieved statistical significance,
they did not use predetermined power calculations. Third, the Boyer protocol differs in key
respects from the protocol used today for intrapartum prophylaxis. The “at risk” neonates in the
study were treated with intramuscular ampicillin following birth (neonatal cultures were taken
prior to administration of intramuscular ampicillin); the intrapartum antibiotic was ampicillin
instead of penicillin; and neonates were identified for receipt of intrapartum antibiotics according
to different criteria than we use today. These are not limitations of the study itself, but it does
prevent us from making inferences about the current CDC recommended protocol based on the
results of Boyer et al.

Another study published in 1987 concurred with the results of the Boyer study. Teres et al50
performed a study in which they randomized pregnant women to receive ampicillin or no
treatment. The colonization rate in neonates born to mothers treated with ampicillin (n=57) was
3.3% vs. 42.9% of those not treated with ampicillin (n=64). This data was reported to be
statistically significant although an exact p-value was not reported. The study also showed a
significant difference between the neonates in regard to neonatal group B streptococcal sepsis;
1.8% of infants born to mothers treated with ampicillin had group B streptococcal septicemia
whereas 13% of neonates born to untreated women had group B streptococcal septicemia
(p=0.04).50 The rates of septicemia in this study were incredibly high when considered against
the background rate of neonatal group B streptococcal sepsis at the hospital at which the study
was performed (1 case per 1,000 live births). The high rates of septicemia observed are
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concerning and raise concern that the population may not be representative due to some form of
selection bias.

In 1990, a group of concerned parents formed the Group B Strep Association. The
organization‟s mission was to advocate for prevention of neonatal disease. Broad media
coverage ensued and based on this pressure and the data from the Boyer and Teres studies, the
first formal recommendations about intrapartum prophylaxis for group B streptococcal disease
were made by the American Association of Pediatrics (AAP)41 and the American College of
Obstetricians and Gynecologists (ACOG)51 in 1992. The ACOG Guidelines were not as farreaching and not as specific as the AAP guidelines. The Boyer and Teres studies are the only
studies that were cited by the AAP in support of the efficacy of intrapartum prophylaxis. The
AAP guidelines recommended that all pregnant women should be screened for group B
streptococcus by culture performed at 26-28 weeks of gestation. Women with a positive group B
streptococcal culture and one or more of the defined risk factors were recommended to receive
intrapartum ampicillin. The risk factors were (1) preterm labor (gestational age less than 37
weeks), (2) premature rupture of membranes at less than 37 weeks gestation, (3) fever during
labor, (4) multiple births, and (5) rupture of membranes greater than or equal to 18 hours prior to
delivery at any gestational age. They also recommended that any woman who had previously
delivered an infant with invasive group B streptococcal disease should receive intrapartum
prophylaxis in each of her subsequent pregnancies.

The ACOG recommendations differed from the AAP recommendations in a few ways. First,
they did not recommend a specific gestational age at which prenatal cultures should be
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performed. Second, they recommended that either penicillin or ampicillin could be used for
prophylaxis instead of a preference for ampicillin as recommended by AAP. Third, they made
no recommendation about the duration of prophylaxis (AAP recommended 4 hours of
prophylaxis before delivery). Fourth, the risk factors were the same with the exception of
multiple births, which are not included in the ACOG recommendations and the addition of a
previous sibling born with invasive group B streptococcal disease as a risk factor. The
approaches put forward by both ACOG and AAP to administering intrapartum prophylaxis were
later deemed a “risk factor based approach” as only women with risk factors and positive group
B streptococcal culture were treated. Although these recommendations were based on few
studies which had some methodological flaws as described above these recommendations began
slowly to be adopted nation-wide.

The next update to recommendations regarding neonatal group B streptococcal disease were
made by the Centers for Disease Control (CDC) in 1996.16 These recommendations were
supported by both the AAP and ACOG, but the CDC felt that widespread adoption of the
guidelines in the obstetric community had not taken place and wished to issue guidelines with a
more powerful government backing.52, 53 These recommendations differed from the 1992
recommendations in a number of ways. The most significant was that the CDC now
recommended two alternative approaches to prevention of early onset group B streptococcal
disease: the “screening-based approach” and the “risk-factor based approach”.

In the screening-based approach, all pregnant women would be screened by culture at 35-37
weeks (change in timing from 1992 recommendations) for group B streptococcus. All women

12
who tested positive were recommended to be offered the option of intrapartum antibiotic
prophylaxis and, after being informed of the risks and benefits, should make an informed
decision. Alternatively women could be evaluated using the risk-factor approach. The riskfactor approach had also changed from the 1992 AAP recommendations. It now consisted of
risk factors alone with no group B streptococcus culture performed. The risk factors had also
changed and now included: (1) gestational age less than 37 weeks, (2) duration of membrane
rupture greater than or equal to 18 hours, (3) maternal temperature greater than or equal to 100.4
degrees Fahrenheit or 38.0 degrees Celsius, (4) group B streptococcal bacteriuria and (5) prior
infant with invasive group B streptococcal disease. The presence of one or more risk factors
indicated the need for intrapartum prophylaxis. There were now two viable options
recommended, but the screening approach was presented first in the document and the risk factor
based approach was deemed “an acceptable alternative”. Interestingly, in the flow chart for
decision making which accompanied the recommendations stated that treatment for patients who
had risk factors was to “give intrapartum penicillin” whereas the treatment for those with
positive group B streptococcal cultures was to “offer intrapartum penicillin”.
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Figure 1: Management flow chart from 1996 CDC guidelines instructing clinicians on how to
assess need for intrapartum prophylaxis.16

The CDC also made recommendations about two populations of patients regardless of which
screening strategy was pursued. Pregnant women with group B streptococcal bacteriuria
(whether symptomatic or asymptomatic) should be immediately treated with antibiotics to treat
the bacteriuria. Furthermore, because bacteriuria represented such a high burden of bacterial
colonization, those women would receive intrapartum antibiotics at delivery independent of the
time of diagnosis of bacteriuria and even if it was successfully treated. The other population,
women who had previously delivered an infant with invasive group B streptococcal disease, was
recommended to universally be treated with intrapartum prophylaxis.
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One of the major changes in the 1996 CDC recommendations from the 1992 AAP and ACOG
recommendations was for culture to be performed at 35-37 weeks gestation instead of 26-28
weeks gestation. Screening at 35-37 weeks had not been validated in large clinical trials, but an
early study, Yow et al published in 197947 recommended screening at 34-36 weeks based on the
results of their own colonization studies in pregnancy54 as well as data from longitudinal
colonization studies done in 1978 which showed that women could be culture negative in the
weeks before birth, but become culture positive at the time of birth55. The authors of that paper
speculated that the closer to labor the cultures could be performed the more accurate they were
likely to be. Analysis of data from the Boyer study did show that the closer to delivery screening
cultures were collected, the higher the predictive value of the cultures.56 A large clinical study in
Australia had also used cultures at 32 weeks gestation to evaluate for group B streptococcal
carriage.37 There were also changes in the definition of risk factors. First, the temperature that
defined fever was adjusted upwards from 37.5 to 38.0 degrees Celsius. The reasons for this
change are not elucidated or addressed in the recommendations. The second change was the
exclusion of multiple gestations as a risk factor. This was based on evidence from large studies
which suggested that multiple gestations was not a significant independent risk factor and was
likely a risk factor due to its association with prematurity.38, 57

The 1996 CDC recommendations represented a shift from the 1992 recommendations of ACOG
and the AAP. Whereas in 1992 patients needed to have both a positive group B streptococcal
culture and the presence of a risk factor to be considered “at risk” of having a neonate develop
early-onset invasive group B streptococcal disease; now, the presence of either a risk factor or a
positive culture was sufficient. Studies available in 1996 indicated that treating women
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identified with the risk factor based approach that represents 4.6% - 8.9% of the obstetric
population.48, 58 Data on colonization of pregnant women quoted in the 1996 CDC
recommendation stated that 10-30% of women were colonized with group B streptococcus,
representing a much larger group of individuals.16 What new evidence had come to light in those
four years that caused this shift that represented treating many more women? All of the 6 studies
quoted in the 1996 recommendations which supported the use of intrapartum antibiotic
prophylaxis for “unselected women colonized with group B streptococcus”16 were done between
1979-1991.37, 46, 47, 59-62 It was not any new information or data that caused the introduction of
universal screening, but rather a reassessment of previously collected information. The
reinterpretation of these studies or rationale for this shift in thinking are not explained or
addressed in the guidelines. The authors state that the incidence of group B streptococcal disease
has not decreased although data from these six studies show that intrapartum prophylaxis can be
effective at preventing transmission of the organism. They state that the reason the incidence has
not declined is that not enough patients are being exposed to intrapartum prophylaxis. The
reassessment of the guidelines performed in 1996 seemed to have been designed to encompass a
larger group of women.

Following the introduction of the guidelines in 1996 there was a shift towards increased
utilization of chemoprophylaxis across the country. A national survey of ACOG members in
2000 showed that 98% had a policy regarding group B streptococcus and that 75% were using
the universal screening approach.63 As a result of this increased chemoprophylaxis, the rates of
early onset invasive neonatal group B streptococcal disease dropped. The incidence was 2-3
cases per 1,000 live births before the guidelines were instituted, but by 1999, the incidence had
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decreased to 0.5 cases per 1,000 live births, a reduction in incidence of 70%.22 The incidence of
group B streptococcal infection among pregnant women, such an endometritis and amnionitis,
also declined from 0.29 per 1,000 births in 1993 to 0.23 in 1998, representing a reduction of
21%.22

FIGURE 2: Trends in incidence of invasive neonatal group B streptococcal disease
over time with superimposed dates of implementation of guidelines and
recommendations. Figure taken from 2002 CDC Guidelines.9

In 1996, there had not been any studies which compared the risk factor based approach and the
universal screening approach. Furthermore, it was thought that the universal screening approach
would be much more difficult to implement and so both options were deemed appropriate until
further evidence was available. That further evidence came in 2002 with the publication of a
large CDC-sponsored multi-center retrospective cohort study published in the New England
Journal of Medicine that directly compared the two approaches: Schrag et al.49 The study
examined a sample of 5,144 births representing a population of over 629,912 live births in eight
distinct geographical areas. They found that the relative risk of early-onset group B
streptococcal disease was significantly lower among the neonates born to mothers in the
universal screening group as compared with the risk-based group (RR=0.46, CI – 0.36-0.60).
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The screening approach was 50% more effective that the risk factor based approach. This
difference between the two approaches persisted even after controlling for increased presence of
known risk factors for group B streptococcal disease present in the risk factor cohort. Based on
this study and the results of smaller individual hospital based studies that also showed a benefit
of the universal screening approach,64-67 the CDC again revised the guidelines in 2002. It now
recommended that all pregnant women are screened at 35-37 weeks gestation for group B
streptococcus and, if positive, be treated with intrapartum antibiotic prophylaxis. The risk factor
approach was no longer considered an adequate alternative.

Other benefits to the universal screening approach were noted in the 2002 CDC
recommendations. First, the authors expressed that the universal screening approach was more
straightforward to implement and as a result more women in the universal screening groups
received antibiotics (40-80% in the risk factor groups64, 68-70 and 90% in the universal screening
groups64, 66, 71-76). Second, an assumption based on the data available in the 1996
recommendations was that universal screening would expose a larger cohort of women to
intrapartum antibiotics (see data provided in above section on 1996 recommendations).
However, data cited in the 2002 recommendations now stated that perfect implementation of
both the risk factor and universal screening strategies would result in intrapartum antibiotic
prophylaxis rates of 24%, because women who are culture negative for group B streptococcus,
but do have risk factors were not to be treated with antibiotics.22, 49 Therefore, the two strategies
could no longer be differentiated on the basis of how many women and their neonates would be
exposed to antibiotic prophylaxis. Third, although the culture and follow-up documentation of
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cultures do represent a cost, in regards to cost efficacy, the 2002 recommendations expressed that
the strategies did not differ by overall cost savings due to disease prevention.77, 78

The 2002 guidelines were also the first guidelines that made recommendations about how to
manage neonates exposed to intrapartum prophylaxis. The 1996 recommendations stated that
there was not enough experience or evidence to offer suggestions on management of infants who
had received prophylaxis.16 But, in the 2002 recommendations a flow chart was provided [Figure
3] that divided infants into two groups depending on whether or not they had received four hours
of intrapartum prophylaxis.

FIGURE 3: Sample algorithm for management of newborns exposed to intrapartum

prophylaxis presented in CDC 2002 Guidelines. A clear division of management is made
based following the “duration of IAP before delivery <4hrs?” box.9
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If a woman had received less than four hour of prophylaxis it was recommended that her child be
observed for greater than 48 hours (as most cases of early onset disease present in the first 24
hours) in the hospital to watch for signs of sepsis and a “limited evaluation” should be
performed. It was also recommended that if an infant is born at a gestational age greater than 38
weeks and has a mother who received greater than four hours of intrapartum prophylaxis, that
infant may be discharged to home as early as 24 hours after delivery. The recommendations
created two distinct groups of infants to be managed differently based on whether or not they had
received adequate prophylaxis according to what has become known as the “four hour rule” on
labor floors across the country.

As discussed previously, following the introduction of the 1996 recommendations and the
adoption of intrapartum prophylaxis the rate of invasive group B streptococcal disease
decreased. From 2000 until 2003 the incidence further decreased from 0.52 to 0.31 cases
per 1,000 live births. Unfortunately, from 2003-2006 the incidence increased, from 0.31
to 0.40. Interestingly, this increase in the incidence was driven by an increase in disease
among African-American term infants. The incidence among African-American infants
was 2.8 times higher than the incidence among Caucasian infants. A higher incidence
among black infants has been demonstrated since rates of group B streptococcal disease
have been monitored. The reasons for the racial discrepancy are unknown. It is also
unclear why the rates of early onset sepsis have decreased in a higher proportion among
Caucasian infants in response to intrapartum prophylaxis compared with AfricanAmerican infants.
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Figure 4: Rate per 1,000 live births of early-onset group B streptococcal disease from 20002006 according to CDC.18

The majority of the evidence-base for the recommendations of the CDC come from studies of the
Active Bacterial Core (ABC) surveillance system data. This is a ten-state database operated and
managed by the CDC, which conducts active population-based surveillance for invasive group B
streptococcal disease. All information about incidence in the United States population is
collected from this database. Because the incidence of group B streptococcal disease is so low,
performing randomized controlled trials to investigate the role of intrapartum prophylaxis to
prevent group B streptococcal disease or the question of the risk factor based approach vs.
universal screening approach is impractical. As a result, the studies that examine the ABC data,
the only data set large enough to explore the outcome of group B streptococcal disease, are
retrospective cohort studies. There have been two studies based on the CDC ABC data that
explore issues surrounding the receipt of intrapartum antibiotics: Schrag et al 20029, and
VanDyke et al 200923. The only other papers published using the ABC data include papers
examining incidence of neonatal disease, disease burden in adults, and antimicrobial resistance.
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Schrag et al49 estimated the relative risk of group B streptococcal disease associated with various
variables. They found that universal screening for group B streptococcus was associated with a
decreased relative risk of development of neonatal group B streptococcal disease. Medicaid
payment, group B streptococcal bacteriuria, preterm delivery, prolonged rupture of membranes,
inadequate prenatal care, black race, maternal age less than 20 years, previous infant with group
B streptococcal disease and intrapartum fever were the other variables for which a relative risk
was calculated.49 Missing from this list of variables is receipt of intrapartum antibiotics. The
absence is very curious. Although, 89% of women in the universal screening group received
antibiotics and only 61% in the risk factor group received antibiotics, only the two approaches of
universal screening vs. risk factor are compared. The relative risk of receipt of intrapartum
antibiotics vs. no antibiotics is not compared, although it is clear that the authors did collect data
on receipt of antibiotics. Without comparing these two groups head to head, it is not clear that
the success of the universal screening approach relies on intrapartum antibiotics. Instead, it may
be that clinicians treat women with a positive group B streptococcus culture differently than a
woman with unknown colonization status. They may treat them more aggressively, perhaps
admitting them earlier in the labor process or performing Cesarean section rather than allow a
longer duration of ruptured membranes. Without calculating the relative risk of receipt of
antibiotics specifically we cannot assume that the success of the universal screening approach
relies on intrapartum antibiotics. The fact that the authors reported the relative risk for so many
different variables, but not intrapartum antibiotics, even though they had the data to do so, is
puzzling.
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A more recent paper using the ABC data examined the implementation of the 2002 guidelines to
examine missed opportunities for disease prevention and to characterize the remaining burden of
group B streptococcal disease in the era of intrapartum prophylaxis. Similar to Schrag et al
2002, this paper did not address the issue of clinical efficacy of intrapartum prophylaxis although
the data to do so was available. The paper reported that there had been broad uptake of the
guidelines. In 1998-1999 the percentage of women who were screened for group B
streptococcus was 48.1%, this rose to 85.0% in 2003-2004. The percentage of women with an
indication for intrapartum antibiotics who received antibiotics also increased from 73.8% to
85.1%. They identified groups of women who were less likely to receive intrapartum
prophylaxis when indicated. These included women who deliver preterm with unknown
colonization status, women who are allergic to penicillin, and women with false negative
screening results (61.4% of the mothers of infants with group B streptococcal disease were
culture negative). They also addressed the issue of racial disparity in incidence of disease.
There was no difference between races in screening rates or in rates of receipt of intrapartum
antibiotics. The reasons for the racial disparity in rates of early onset GBS disease remained
elusive. Again, as in the other ABC data based paper, Schrag 2002, receipt of IAP was also not
one of the factors analyzed.

As mentioned above, the ABC data is the only data set that is large enough and currently
available to perform an outcome-based assessment of the clinical efficacy of intrapartum
antibiotics and optimal duration of antibiotic treatment. This analysis has not been done for
unclear reasons. However, a recent Cochrane review attempted to answer this question.20 The
primary aim of the review was to assess the effect of intrapartum prophylaxis in reducing
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mortality from group B streptococcal disease. Secondary objectives included assessing the effect
of intrapartum prophylaxis on vaginal colony counts and maternal outcomes such as
chorioamnionitis, sepsis, urinary tract infections, etc. The review was only able to identify three
randomized controlled trials that fit inclusion criteria. They noted that these trials were all
performed 20 years ago and had serious concerns for bias. Based on these trials they found that
there was not sufficient evidence to support a decrease in neonatal mortality as a result of
intrapartum prophylaxis. They did note a reduction in the incidence of group B streptococcal
sepsis in neonates treated with intrapartum prophylaxis. The issue of antibiotic selection was
also evaluated and the conclusion was reached that there is no conclusive data to support the use
of penicillin over ampicillin or ampicillin over penicillin as the antibiotic of choice. The
Cochrane review concludes that the use of intrapartum antibiotics to prevent group B
streptococcal disease is not supported by conclusive evidence. Given that guidelines have
already been put into place with regards to intrapartum prophylaxis for group B streptococcal
disease it may not be feasible to perform randomized controlled trials making the ABC cohort
data all the more important in addressing this question. In fact, the 2002 guidelines rest almost
exclusively on the evidence provided by Schrag et al 2002 based on ABC data.

Optimal Duration of Antibiotic Prophylaxis
In order to be effective, it is hypothesized that intrapartum prophylaxis requires the antibiotic to
cross into the fetal circulation as well as enter the amniotic fluid via fetal micturition. The
antibiotic is also hypothesized to function by attaining sufficient maternal serum concentrations
to decrease colony counts in the vaginal canal; therefore, decreasing transmission of the
organism to the neonatal mucous membranes. Throughout the history of policy and guidelines
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for intrapartum prophylaxis, the appropriate duration of prophylaxis to achieve the previously
mentioned goals has remained a question.

A separate arm of the Boyer study, a prospective cohort, published in 1983, was the first to
address the question of appropriate duration of prophylaxis.59 The study found neonatal
colonization rates were 28% when the mothers received less than one hour of ampicillin
prophylaxis and were only 4% when mothers received greater than one hour of prophylaxis. The
one-hour time point was the duration of prophylaxis that made a difference in rates of neonatal
colonization. However, that data is not cited in the 1992 AAP recommendations about duration
of prophylaxis. Instead, the authors chose to use another mechanism to evaluate the appropriate
duration of prophylaxis: the presence of antibiotic in appropriate concentrations in the amniotic
fluid and fetal circulation. They stated the “chemoprophylaxis ideally should be administered at
least 4 hours before delivery. This allows sufficient time to achieve optimal concentrations of
ampicillin or penicillin G in the amniotic fluid as well as in the placental circulation.”41 The data
cited to support this recommendation were from a pharmacokinetic study, Bray et al, performed
in 196679 However, the AAP authors misinterpreted the 1966 study setting off a chain of
citations leading to the modern day recommendations.

The Bray study was performed when ampicillin was first synthesized and introduced as a new
microbial option. The primary aim of the study was to evaluate the concentration of ampicillin in
maternal blood, fetal cord blood and the amniotic fluid to evaluate the possibility of using
ampicillin as a treatment for chorioamnionitis, endometritis and intrauterine infection of the
fetus. As can be seen from Figure 1, levels of ampicillin in the fetal bloodstream reached a peak
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of 6.2 μg/mL one hour after administration. The amniotic fluid levels took longer to rise and rose
in an arc. The peak concentration of 5.20 μg/mL occurred at the 8-hour time point. Levels at 2
hours were 1.0 μg/mL and at 4 hours were 3.5 μg/mL. The minimum inhibitory concentration
for group B streptococcus is 0.04-0.1 μg/mL.40, 56, 80 All ampicillin levels measured between 0-4
hours in the amniotic fluid, maternal serum and fetal serum were above the minimum inhibitory
concentration. Why the authors of the AAP recommendations chose the four hour time point as
significant to achieve amniotic fluid levels which were sufficient to treat group B streptococcus
is entirely unclear. The four-hour time point did not represent a peak concentration, nor do the
authors of Bray et al mention the four hour time point as significant.79 The 1992 AAP guidelines
cite Bray et al to support that “chemoprophylaxis ideally should be administered at least 4 hours
before delivery. This allows sufficient time to achieve optimal concentrations of ampicillin in
the amniotic fluid and placental circulation”. As can be seen from Figure 5, the data from Bray
et al do not support this conclusion.

Figure 5: Ampicillin concentrations in maternal serum, fetal serum and amniotic fluid over
79
time. Measurements taken after administration of 500mg of ampicillin.
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In fact, when Eickhoff first described the problem of neonatal group B streptococcal disease in
1964, he noted that the minimum inhibitory concentration of ampicillin against group B
streptococcus was 0.04 μg/mL (range 0.02-0.1).40 The minimum inhibitory concentration is the
concentration of antibiotic that is required to eliminate visible growth of the organism. This
would suggest that ampicillin levels (25-fold the minimum inhibitory concentration) are
achieved at the one-hour time point and calling into question the recommendation for four hours
of antibiotic prophylaxis. Furthermore, the authors of the 1992 AAP recommendations chose to
use antibiotic levels instead of the data on colonization rates from the Boyer study. Both
antibiotic levels and colonization rates are proxies for the outcome of interest: early-onset
invasive neonatal group B streptococcal disease. Why the authors chose one proxy from 1966
data on drug concentration over the more recent 1986 proxy of neonatal colonization data is
unclear. Furthermore, the Bray study is cited repetitively over the years as evidence for a
duration of four hours of intrapartum prophylaxis against group B streptococcus despite the fact
that it did not show the four hours of prophylaxis was necessary nor address group B
streptococcus as an organism of interest.

Based on the Bray data, ampicillin persisted as the drug of choice for intrapartum prophylaxis
until the 1996 recommendations, which recommended penicillin G as the antibiotic of choice in
place of ampicillin. A short paragraph is devoted to this change and argues that ampicillin and
penicillin have the same activity against group B streptococcus; however, penicillin has a
narrower spectrum of activity and therefore decreases the chance of selecting for resistant
organisms through the use of intrapartum prophylaxis. It is also noted that both ampicillin and
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penicillin cross the placenta and achieve bactericidal levels in fetal tissues. The only reference
for this entire idea of changing antibiotics is a short article published in 1994 by Amstey.81 The
article is an argument/opinion piece and makes a case for the use of penicillin G over ampicillin.
Amstey states that the strongest reason for use of penicillin over ampicillin is the narrower
antimicrobial spectrum. He also notes that the minimum inhibitory concentration of penicillin G
(as it was calculated at the time) for group B streptococcus (0.02 μg/mL, range 0.01-0.04) is
slightly smaller than the minimum inhibitory concentration of ampicillin for group B
streptococcus (0.04μg/mL, range 0.02-0.1). Furthermore, he argues that both ampicillin and
penicillin G have been evaluated pharmacokinetically and are known to cross the placenta
readily.82 No references to studies that document the rate of crossing the placenta are made. He
concludes that, “Future clinical trials should compare penicillin to ampicillin prophylaxis for
group B streptococcal infection of the neonate”.81

In the 1996 recommendations, only two of the six studies cited to support intrapartum
prophylaxis to prevent neonatal group B streptococcal disease studies used penicillin instead of
ampicillin. One study done in Australia used penicillin (1 million units intravenously, every six
hours) and found a significant reduction in mortality from invasive group B streptococcal disease
in neonates of treated women (untreated n = 26,915, treated n = 30,197).37 Another study used
benzyl penicillin (600 mg intramuscularly at 8 hour intervals) and found neonatal colonization of
3% in the antibiotic group (n=38) and 45% in the untreated group (n=49) (p<0.001).60 The other
four studies used to support intrapartum prophylaxis all used ampicillin. At the time there was
one other study that used a penicillin G dosing regimen. The study used fast latex agglutination
testing to identify women with heavy vaginal colonization. 199 women were identified using
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this approach and randomized to receive penicillin or antibiotic. The neonates of penicillin
treated mothers had a lower incidence of early-onset group B streptococcal disease (1.1%) when
compared with the controls (9.0%) (p<0.01).83 However, the study population only included
heavily colonized women and so was not included as support for use of intrapartum antibiotics in
the culture positive population.

Based on this argument set forward by Amstey, the antibiotic recommendations were changed to
penicillin G. The dosing regimen proposed was a 5 million-unit infusion of penicillin G
intravenously upon presentation to the labor floor, followed by 2.5 million units every 4 hours
until delivery. Ampicillin was considered an alternative antibiotic, but an inferior one due to its
wider spectrum. The ampicillin-dosing regimen recommended was 2 grams intravenously upon
arrival to the labor floor, followed by 1 gram every 4 hours until delivery. It has previously been
discussed that the origin of a four hour interval dosing regimen for ampicillin was based on little
data; however, this four hour dosing regimen using ampicillin had been used and tested in the
seminal Boyer et al New England Journal of Medicine paper which showed it was effective in
reducing neonatal colonization. Why a four-hour interval for penicillin was chosen as well is not
clear. The studies up to this time point using penicillins had not used four hour dosing intervals
nor had penicillin G been used in most of the studies. Furthermore, although both penicillin and
ampicillin belong to the same drug family, penicillin differs pharmacokinetically in that it is
bound to protein at a different rate than ampicillin. It seems that the assumption was made that
penicillin G behaved enough like ampicillin to use a four-hour dosing regimen as well. The
assumption is not made explicitly and the rationale for that assumption is not addressed in the
recommendations; nor are any sources cited which address the question of dosing regimen and/or
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appropriate duration of prophylaxis with regards to the penicillin family or penicillin G
specifically.

The 2002 CDC recommendations continued to advocate a dosing regimen of a 5 million-unit
infusion of penicillin G, followed by 2.5 million units every 4 hours until delivery. The
recommendations cited “new evidence that 4 or more hours of intrapartum ampicillin or
penicillin prophylaxis administered according to recommended dosing intervals significantly
reduces vertical transmission of group B streptococcus and the risk of early onset group B
streptococcal disease”.9 The authors of the recommendations favored using a minimum of four
hours of prophylaxis in contrast to a minimum of two doses of prophylaxis (i.e. the loading dose
and the first dose of 2.5 million units at the four-hour time point) advocated by the AAP in their
1997 recommendation. The papers cited to give support to a duration of four hours were Pylipow
et al 199484 Lin et al, 200185 and DeCueto et al, 199886.

In 2006, a systematic review on the topic of appropriate duration of prophylaxis only identified
four studies which addressed duration of prophylaxis (the three cited above and an additional
one).45 All four studies included a patient population of women with risk factors for group B
streptococcal disease, not a universal screening population.59, 84-86 Three of the studies used
ampicillin antibiotic regimens exclusively59, 84, 86 and one study examined patients who had
received either ampicillin or pencillin.85 One study showed that greater than 1 hour of
prophylaxis was effective in reducing neonatal colonization,59 while two studies showed that
greater than 2 hours of prophylaxis were effective.85, 86 One study was inconclusive. The
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conclusion of this review was that an evidence base for an optimal duration of four hours as
compared with any other duration is lacking.

Pylipow was a retrospective cohort study that examined a population of patients who were group
B streptococcus culture positive and had obstetric risk factors. Furthermore, the antibiotic
regimen used was ampicillin. The study showed that neonates of pregnant women who received
two doses of ampicillin (4 hours apart) had lower rates of group B streptococcal colonization.
However, the study was inconclusive about the optimal duration of prophylaxis.

The Lin study was a retrospective case-control study that compared neonatal cases of group B
streptococcal disease with controls. These patients received both ampicillin and penicillin
dosing regimens as well as alternate antibiotics (patients treated with antibiotics for
chorioamnionitis such as clindamycin were also included in the intrapartum prophylaxis group)
and patients were treated according to the risk factor based protocol, not the universal screening
protocol. The conclusions of this study were that in order to achieve maximum protective effect,
the first dose of antibiotic should be administered at least two hours before delivery.

The DeCueto study is a colony count study which measured neonatal colonization with group B
streptococcus and showed that 46% of neonates were colonized at birth when exposed to 1 hour
of prophylaxis, 28% at 2 hours of prophylaxis and only 1-3% were colonized at the 3 and 4 hour
time points.86 The antibiotic regimen was ampicillin, however, the cultures were not taken
prenatally, rather they were taken at the time of admission to the hospital. This means that all
women in the study had to wait for culture results before being treated. Culture results were
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available 12 hours after admission in 65% of the patients and at 18 hours after admission in 95%
of the patients. Therefore, all women in this study had labors that were longer than 12 hours and
given that rupture of membranes for an extended duration is a risk factor, this is an
unrepresentative patient population.

None of these studies was performed in the population of interest: women with no obstetric risk
factors, but positive group B streptococcal cultures (the universal screening population). Two
used ampicillin and one suggested that two hours of penicillin prophylaxis was sufficient. The
cited studies do not support the concept that a minimum of four hours of penicillin G prophylaxis
is necessary to ensure adequate treatment among patients identified by the universal screening
approach.

As described above, there has been little evidence cited to support the selection of duration of 4
hours as optimal for intrapartum prophylaxis. Additional evidence regarding duration of
intrapartum prophylaxis has been cited from the pharmacokinetic literature. These studies rely
on the premise that intrapartum prophylaxis functions through three mechanisms: 1) decreasing
vaginal colony counts 2) achieving sufficient antibiotic concentration in the amniotic fluid and 3)
achieving sufficient antibiotic concentration in the fetal circulation. Of note, we do not know
which of these mechanisms is most important; all three are hypothesized mechanisms of action
of intrapartum prophylaxis. Data on colony counts and fetal colonization studies have been the
most commonly used proxy to study invasive group B streptococcal disease; however few
studies have examined colony counts in relation to duration of prophylaxis. The most recent
study examined vaginal colony counts during delivery in patients undergoing the recommended
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CDC dosing regimen of penicillin G. Vaginal colony counts declined 5-fold after 2 hours of
prophylaxis and by 4 hours of prophylaxis, colony counts had decreased 50-fold.87 It is not
known what the critical colony count below which the risk of fetal infection decreases. Does the
colony count needs to be zero, or is there some amount of organism that the neonate can tolerate.
The authors of this study concluded, “this has potential clinical significance in that women
commonly deliver less than 4 hours after the penicillin G loading dose, given that babies born to
these women may be kept for prolonged observation unnecessarily.”

Data from the pharmacokinetic literature attempts to demonstrate that intrapartum prophylaxis is
effective by documenting sufficient concentrations of antibiotic in amniotic fluid and fetal
circulation (mechanisms 2 and 3). The most often cited publication on this topic by Bray et al. in
1966 demonstrated bactericidal ampicillin levels above the minimum inhibitory concentration in
amniotic fluid at the first time point measured which was 2 hours after a 500mg maternal
intravenous ampicillin infusion. Ampicillin concentration in the amniotic fluid continued to rise
until 8 hours after the initial infusion.79 In 1974, a similar study found that ampicillin levels
greater than 1.5 μg/ml were detected in the amniotic fluid one hour following an infusion of 1-2
grams of ampicillin in women in labor, which the authors depict as exceeding the minimum
inhibitory concentration for group B streptococcus.88

More recent work, using high-performance liquid chromatography on sera collected at elective
cesarean section after a 2g maternal infusion of ampicillin, demonstrated ampicillin levels in
maternal and fetal sera exceeding the minimum inhibitory concentration for group B
streptococcus within 3 minutes of infusion.89 Likewise, bactericidal concentrations of ampicillin
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were found in amniotic fluid as early as 5 minutes after infusion. The only study to date on the
pharmacokinetics of penicillin G in pregnancy examined maternal serum levels only and was
published in 2001. This study demonstrated that maternal levels of penicillin G exceeded the
minimum inhibitory concentration for group B streptococcus 5 minutes after a 1 million-unit
infusion of penicillin G. After 4 hours, the average maternal serum concentration was still 120fold greater than the minimum inhibitory concentration.80

To date, there has been no study that examines penicillin G levels in either amniotic fluid or fetal
circulation nor have there been studies that examine the pharmacokinetics of the recommended
CDC penicillin G dosing regimen. In the first portion of this study, we sought to examine the
amount of time required after maternal infusion of penicillin G to achieve the minimum
inhibitory concentration for group B streptococcus in fetal serum and to examine the fetal
pharmacokinetic profile of this maternal penicillin G dosing regimen over time, in order to
partially address the question of the validity of the recommended optimal duration of four hours
of antibiotic prophylaxis.

As discussed previously, based on the 2002 CDC guidelines, a maternal-infant dyad is
considered adequately treated if the mother has received four or more hours of
prophylaxis before delivery (the “four hour rule”). However, there are no stated
recommendations to attempt to prolong the course of labor to achieve this duration. If the
mother has received less than four hours of prophylaxis, infants are recommended to
undergo a limited evaluation, which may include blood cultures at some institutions, and
to be observed for 48 hours in the hospital. As many as 25-50% of group B streptococcus
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positive women in labor fail to achieve the recommended four hours of antibiotics due
the rapidity of their labors.23, 75 Due to the implicit assumption that four hours of
intrapartum prophylaxis is beneficial and less than four hours is “inadequate”, as well as
institutional protocols being applied to newborns born prior to four hours of therapy, it is
possible that the guidelines have created an incentive for clinicians to deliver neonates
who have received greater than four hours of prophylaxis. In the second portion of this
study, we sought to investigate how clinicians are responding to this created incentive: to
examine if clinicians were altering their care of group B streptococcus positive women in
labor in order to achieve greater than four hours of prophylaxis. We developed a survey
to query clinicians about their interpretation and clinical application of the 2002 CDC
guidelines on prevention of neonatal group B streptococcal disease.

MATERIALS AND METHODS
Patient Recruitment
Laboring group B streptococcus culture positive women who were administered penicillin G by
their medical provider according to the 2002 CDC protocol, as standard of care, were eligible for
the study.

Yale University Institutional Review Board approval was obtained, and patients

were enrolled after obtaining informed consent. Inclusion criteria included: pregnancy 37
weeks; singleton gestation; group B streptococcus carrier status by rectovaginal or urine culture;
and receipt of intravenous intrapartum penicillin G prophylaxis in standard CDC dosing regime
doses. The exclusion criteria included hypertensive or renal disease, multiple gestation,
penicillin allergy, and current other antibiotic usage. Following consent, duration and timing of
antibiotic infusions, maternal height, weight, and demographic information were all recorded

35
from patient charts. Based on estimated means and variances from Johnson et al80, we estimated
that we required 10 patients in each time interval (<1 hr, 1 to <2 hrs, 2 to <3 hrs, 3 to <4 hrs, 4
hrs), to achieve >80% power to detect penicillin G concentration statistically greater than the
minimum inhibitory concentration (0.1 g/ml), alpha=0.05.

Umbilical cord blood samples were obtained from the Yale New Haven Hospital blood bank,
which stores samples for blood typing of all infants. The blood was stored in glass tubes labeled
with patient name and medical record number at 4ºC for one week until a research team member
collected them. The blood was then centrifuged at 3000g for 15 minutes and stored in 0.5mL
aliquots at -80ºC until high-performance liquid chromatography (HPLC) analysis. This approach
was validated by comparing penicillin G levels in fresh cord blood collected at delivery to blood
bank samples in 18 subjects.

High-performance liquid chromatography
The penicillin G concentration was measured by high-performance liquid chromatography and
ultraviolet detection (HPLC-UV). The ESA reverse-phased HPLC system (Chelmsford, MA)
was equipped with two dual piston pumps (Model 582), a refrigerated autosampler (model 542),
high-pressure mixer and an ESA Model 528 UV-VIS detector. It was controlled and data
acquired using ESA CoulArray for Windows software. An Intersil ODS-3 C18 column (150 x
4.6 I.D.), 5 μm particle size (GL Science Inc, Japan) was protected with a Platinum C18 (7.5 x 4.6
mm I.D.) 5 μm particle size guard column (AllTech GmbH, USA). The mobile phase was
prepared using 0.05 dihydrogen phosphate (99.99% purity, pH 5.0; VWR International, West
Chester, PA) and acetonitrile (90:10 vol/vol; Fisher Scientific, Fair Lawn, NJ). Serum samples
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were analyzed at a gradient condition with mobile phase A of 0.05M sodium dihydrogen
phosphate in 10% acetonitrile (PH=5) and B of 100% acetonitrile. The internal standard (IS)
was prepared by dissolving 2.5 mg of ampicillin sodium salt (potency 98%; Sigma Chemical
Company, St. Louis, MO) in 5 mL of HPLC grade water (Fisher Scientific, Fair Lawn, NJ) to a
final stock concentration of 0.5 mg/mL. Penicillin sodium salt (5 mg, potency 99%; Sigma
Chemical Company, St. Louis, MO) was dissolved in 5mL of HPLC grade water to a final stock
concentration of 1 mg/mL. Serum standards for penicillin G were prepared in blank serum at 2.5,
5, 10, 20, and 40 μg/mL to create a standard curve for quantification (r=.9997). Both patient
serum samples and serum standard curve samples were deproteinated by adding 100 μL of
sample to 108 μL acetonitrile/ampicillin(IS) solution for a final concentration of 40 μg/mL of IS
for each sample. Samples were vortexed for 15 seconds, placed at 4ºC for 10 minutes, and then
centrifuged at 3000g for 10 minutes. 100 μL of aqueous phase from each serum sample was
transferred to a clean autosampler vial. A 25 μL sample was injected onto the column at a flow
rate of 1.0 mL/min. Both penicillin G and ampicillin (IS) were detected at 200 nm. Ampicillin
and penicillin G had elution times of 2.28 and 13.2 min respectively. The CV was calculated by
running three samples in three separate runs (CV = 2.9637; accuracy range: ± 3%). Additionally,
every single run contained a serum standard curve point of known concentration. The calculated
CV for those samples was 2.12%, verifying accuracy for all samples on each run. The lower
limit of detection of penicillin G sodium was 0.192 μg/mL. A blank serum sample was also run
and showed no evidence of a penicillin G peak ruling out the possibility of carry over from run to
run. The concentration of penicillin G sodium salt was quantified by comparing peak height ratio
(penicillin G/IS) from the unknown cord serum samples and those obtained from the penicillin G
standard curve.
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Statistical analysis was performed using Student‟s t-test, analysis of variance, and multivariable
linear regression using SAS 9.1 software.

Clinician Survey
We designed a survey to query clinicians about their interpretation of the 2002 CDC
guidelines. The Human Investigation Committee at Yale University approved the survey.
The focus of the survey addressed whether or not clinicians alter their management of
labor in response to the 2002 protocol by asking a series of questions using clinical
scenarios. We also addressed clinician perceptions of the protocol and any perceived
patient or provider stress they had observed.

This survey was offered to all midwives, resident physicians and attending physicians
who have privileges on the labor and birth unit of Yale-New Haven Hospital, which has
approximately 4,700 deliveries annually, of which about 20% occur in the setting of
maternal group B streptococcus colonization. Surveys were distributed in three ways:
providers were given surveys at Grand Rounds for the Department of Obstetrics and
Gynecology at Yale University; surveys were made available on the labor and delivery
floor of Yale-New Haven Hospital; and surveys were distributed by e-mail. All surveys
were confidential and collected in a sealed box to preserve anonymity. When surveys
were collected, respondents‟ names were checked off a list to ensure that a single
individual did not return multiple surveys.

38
RESULTS
Stability of Penicillin G in cord blood
The primary aim of the pharmacokinetic portion of this study was to evaluate women who
delivered quickly (less than 4 hours) and thus did not receive the duration of prophylaxis
recommended by the 2002 CDC Guidelines. Obtaining cord blood samples on the labor floor for
these rapidly progressing deliveries is logistically difficult, while obtaining blood bank samples
after delivery is more straightforward. After obtaining and processing 18 labor floor obtained
cord blood samples and the blood bank obtained cord blood samples from the same patients,
penicillin levels were determined by HPLC and compared. For all 18 samples, the levels of
penicillin G were very close to one another. The penicillin level was consistently slightly lower
in the blood bank samples when compared with the delivery floor samples. The percent lost
ranged from .40% to 16.40% with a mean of 9.54 ± 4.76%.
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Figure 6: Blood bank and labor floor umbilical cord serum sample penicillin G

concentration measured for 18 patients. Each patient has one of each sample and
patients are organized in order of increasing penicillin G concentration, from left to right.
The solid circles represent the samples obtained on the labor floor and the outlined
circles represent the samples taken from the blood bank after one week of storage.

We performed mathematical modeling to calculate the predicted labor floor concentration based
upon the concentration found in the blood bank sample as well as the percent lost. We then
calculated the predicted labor floor concentration based on the blood bank concentration for each
of the samples. However, the mathematical modeling introduced an inherent component of
variability, as we were no longer working with HPLC data, but rather calculated predicted
concentrations. The primary aim of the study is to determine if cord blood levels above the
minimum inhibitory concentration are achieved when women receive less than 4 hours of
prophylaxis. By analyzing the blood bank values, our data and conclusions contain a degree of
underestimation. We used this conservative approach because if the underestimated values from
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the blood bank were significant, than by extension, values at the time of delivery would also be
significant.

Dosing Regimen
After confirmation of the feasibility of using blood bank samples to measure penicillin G levels
in cord blood, an additional 80 maternal-infant dyads were included in the study. Consent was
obtained consistent with standards of the IRB at our institution. One-hundred-ten eligible
patients were approached at Yale-New Haven Hospital from June 6th, 2007 until August 14th,
2007. Ninety-eight patients consented to participate, yielding a participation rate of 89%.
Reasons for non-participation included lack of time or desire to discuss the study or to read and
sign the consent form. The cohort was representative of the population served by our urban,
academic medical center; demographic and clinical characteristics of the patients enrolled are
listed in Table 1.
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Table 1. Demographics. Characteristics of 98 patients who gave informed consent
and were enrolled in the study.

Maternal Age
Maternal BMI at Delivery
Gestational Age
Neonatal Weight
Gravidity
Parity
Race
White
Black
Latina
Asian
Other
Provider Type at Delivery
Physician
Midwife
Site of Prenatal Care
Private
Hospital Clinic
Type of Birth
NSVD
Caesarean Section

28.5 ± 6.5 yrs
31.6 ± 5.9
39.3 ± 1.2 wks
3338.4 ± 450.9 g
2 (1, 3: 2)
1 (0, 2: 2)
49 (50%)
20 (20.4%)
22 (22.5%)
5 (5.1%)
2 (2%)
65 (66.3%)
33 (33.7%)
60 (61.2%)
38 (38.8%)
76 (77.6%)
22 (22.4%)

*Data for continuous variables is presented as Mean  Standard Deviation or median (1st quartile, third
quartile: interquartile range).
*Data for categorical variables are presented at Number of Patients (Percent of Total Patients).

For all patients in the study, the number of minutes from first dose administration until
delivery ranged from 32 to 1473 min with a mean of 352.7±363.5 min. The penicillin G
concentrations for all patients ranged from 1.02 to 17.93 μg/mL with a mean of
6.25±4.15 μg/mL. Patients were divided into 7 groups for analysis [Table 2].
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Table 2. Duration of prophylaxis and fetal serum concentration of penicillin G for all
patients grouped by duration of prophylaxis (minimum inhibitory concentration for GBS
= 0.01μg/ml).

Penicillin G Concentration

Group

Duration Prophylaxis

(#)

(hours)

N

[meanSD] (μg/ml)

1

Less than 1 h

10

11.60  4.49

2

1-2 h

15

9.74  3.42

3

2-3 h

15

6.62  3.75

4

3-4 h

17

3.64  1.80

5

More than 4 h, no 2nd dose

6

2.28  0.89

6

4-8

11

6.88  3.67

7

More than 8 h

24

4.10  2.60

Grouping based upon hour time blocks are presented throughout the literature on this topic, as
time cutoffs are used clinically to determine adequate duration of prophylaxis and assess
neonates at risk for group B streptococcal disease.48, 84, 85, 90 Each of the 7 groups of patients was
compared to the minimum inhibitory concentration for group B streptococcus (0.1 μg/mL)21, 90
using Student‟s t-test. All groups were statistically significantly above the minimum inhibitory
concentration, p<0.002. Furthermore, penicillin G levels observed in each individual cord blood
sample were 10-179 fold above the minimum inhibitory concentration.

Each of the seven groups was also compared with one another using analysis of variance.
Penicillin G levels for those patients receiving less than 1 hour of prophylaxis (group 1) were
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statistically significantly greater (p<0.05) than all other groups of patients receiving greater than
2 hours of prophylaxis (groups 3,4,5,6,7). Rather than requiring four hours to reach levels of
penicillin G above the minimum inhibitory concentration in the fetal bloodstream, we found
statistically significantly higher levels during the 0-2 hour time points when compared with
longer durations, even after subsequent re-dosing with 2.5 million units at four-hour intervals.

For graphical pharmacokinetic analysis, the data for those patients who received only one dose
of 5 million units of penicillin G [Figure 7] were analyzed by using time elapsed since most
recent dose. As can be seen in Figure 7, the relationship between penicillin G concentration and
time elapsed since dose of 5 million units of penicillin G was not strictly linear. The
concentration rose linearly (R2 = .40) [Equation: [Con. penicillin] = 0.255(min) + 1.2718], as the
penicillin G made its way across the placenta and into the fetal circulation, until the one-hour
time point. After one hour, the penicillin G concentration decreased according to a power-decay
model (R2 = .67) determined by optimizing the r2 [Equation: [Con. penicillin] = 2745.5(min)^(1.2503)]. This period represents the combined efforts of both maternal and fetal clearance, as
well as maternal and fetal metabolism. In order to accommodate the non-linearity of penicillin G
levels over time, the time variable was transformed according to the power-decay model
equation above for values greater than one hour. Multiple linear regression analysis performed
on the cohort of all patients showed that fetal penicillin G levels were associated with duration of
exposure to penicillin, time since last dose, dosage, and number of doses, but not maternal BMI.
Assuming maternal BMI is an adequate, though imperfect, marker for maternal size and maternal
volume of distribution, the maternal volume of distribution did not appreciably alter the fetal
cord blood concentrations of penicillin.
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Figure 7. Time After Infusion of Penicillin G vs. Concentration in
Umbilical Cord Serum at Delivery. Relation between time elapsed since initial

dose of 5 million units of penicillin G and concentration of penicillin G in umbilical cord
serum at the time of delivery.

As seen in figure 7, the highest value of penicillin G concentration in the cord blood was
observed at around 1 hour after administration of the loading dose of 5 million units. The lowest
value observed for all patients was 1.02 μg/ml seen in a patient who delivered 5 hours and 34
minutes after receiving her initial dose. Additionally, the group with the lowest mean (2.28
±0.89 μg/ml) was represented by six patients who failed to receive their additional 2.5 million
units at the four-hour time point. For patients receiving maintenance doses of 2.5 million units
every four hours, levels remained consistently above the minimum inhibitory concentration and
decayed in the same fashion as the loading dose. Of note, fetal serum penicillin G levels did not
accumulate with repeated maintenance dosing.
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Clinician Survey
All clinicians surveyed had active privileges on the labor and birth unit of Yale-New
Haven Hospital during the period of survey collection, July 12th, 2007 – September 15th,
2007. A total of 96 clinicians met the criteria to receive the survey, and 70 completed it,
yielding a participation rate of 72.9%. All 70 survey respondents answered all of the
survey questions. Demographics for all respondents are reported in Table 3.
Table 3: Demographics for all 70 clinicians who completed our survey.
Gender
Male
Female
Provider Type
Midwives
Physicians
Residents
Provider Practice Type
Private Practice
Hospital staff/faculty
Patient Insurance Status
> 80% private insurance
< 80% private insurance
Date Completed Training
Before 1990
After 1990
Attended CME on GBS

26 (37.1%)
44 (62.9%)
17 (24.3%)
38 (54.3%)
15 (21.4%)
36 (51.4%)
34 (48.6%)
39 (55.7%)
31 (44.3%)
38 (54.3%)
32 (45.7%)
19 (27.1%)

We asked clinicians how, if at all, they changed their management of group B
streptococcus positive multiparous women compared with group B streptococcus
negative multiparous women. Only 21.4% responded they did not change their
management at all; 35.7% encouraged group B streptococcus positive women to come to
the hospital at the first signs of labor; 11.4% reported that they admitted group B
streptococcus positive women to the hospital before they were in active labor; and 57.1%
said that they admitted group B streptococcus positive women earlier in the course of
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labor than they would normally admit group B streptococcus negative women. We also
specifically addressed the labor course itself and asked clinicians if they recommended
any interventions if a group B streptococcus positive woman had not yet received four
hours of prophylaxis. Only 22.9% of clinicians responded that they would not alter their
management of labor; 21.4% recommended “laboring down”/delay pushing; 27.1%
would turn off or decrease an oxytocin infusion; 74.3% reported that they delay or avoid
artificial rupture of membranes. This data is reported in Table 4.
Table 4: Survey responses from clinicians in response to questions about labor
management of group B streptococcus positive pregnancies in the setting of the 2002
CDC protocol.

Given that the CDC recommends
a minimum of 4 hours of
prophylaxis, do you change your
management of GBS+ multiparous
women in any of the following
ways (check all that apply):

Encourage admission at the first signs of labor
(35.7%)
Admit GBS+ women earlier than GBS- women
(57.1%)
Admit women before they are in active labor
(11.4%)
Make no changes in management (21.4%)

When a GBS+ woman has
received <4hrs prophylaxis, would
you recommend any of the
following to prolong the labor
(check all that apply):

“Labor down” or delay pushing (21.4%)
Delay/Avoid artificial rupture of membranes
(74.3%)
Turn off or decrease oxytocin infusion (27.1%)
Make no changes to prolong labor (22.9%)

The majority (71.4%) of providers said that they would consider a woman who received
4.5 hours of prophylaxis as adequately treated even if she never received a second dose of
penicillin G at the 4 hour time point (Table 4). This is in accordance with the 2002 CDC
guidelines and differentiates from the 1996 protocol16, which required a 2nd dose of
antibiotic even if the woman was in the act of delivering at the 4 hour time point.
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We also solicited their opinions about the 2002 CDC protocol (Table 5). The majority
(55.7%) of clinicians responded that the protocol was “excessive”, while 46.3% described
it as “optimal”. They also responded that trying to achieve four hours of intrapartum
prophylaxis created significant stress for themselves as providers (35.7%), the patient
(54.3%), the labor and delivery floor staff (42.9%), and the patient‟s family (30%).
Table 5: Clinicians’ opinions and interpretations. Survey responses from
clinicians in response to questions about clinician’s opinions and interpretations of the
2002 CDC protocol.

Does the 4 hour prophylaxis protocol cause
additional stress or anxiety to (check all that
apply):
Do you believe that the duration of 4 hours of
intrapartum prophylaxis to prevent GBS
transmission to the neonate is (select one):
Would you consider a woman who received
intrapartum prophylaxis of 4.5 hours
adequately treated if she never received her
second dose of 2.5 million units?

Me, the provider (35.7%)
Patient (54.3%)
Delivery floor staff (42.9%)
Patient‟s family (30%)
Excessive (55.7%)
Optimal (46.3%)
Inadequate (0%)
Yes (71.4%)
No (28.6%)

DISCUSSION
The data presented here demonstrates that shorter durations of exposure to intrapartum antibiotic
prophylaxis are effective in attaining levels of penicillin G in the neonatal bloodstream
significantly above the minimum inhibitory concentration for group B streptococcus. Up until
this point, little has been documented regarding the pharmacokinetic properties of penicillin G in
the pregnant woman and her fetus. Similar studies on ampicillin have shown that ampicillin
levels rise rapidly in the fetal serum following maternal intravenous administration.91 To date,
studies on penicillin G pharmacokinetics have generally been performed on non-pregnant
women or men or neonates themselves (dose given to the neonate after delivery).92-94 One recent
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study examined serum concentrations of penicillin G in pregnancy, but examined only the
maternal circulation and not the fetal.80 Another study gave one IM dose of penicillin G
benzathine and then measured the maternal penicillin G levels at 30 days and fetal levels at the
time of delivery. This study showed levels above the minimum inhibitory concentration at 30
days after injection.95 Our current investigation documents penicillin G levels in the fetus using
the current CDC dosing regimen.

Intrapartum antibiotic prophylaxis likely works to prevent transmission from mother to child by
decreasing colony counts in the vaginal tract at the time of delivery; preventing organism
ascension into amniotic fluid; and achieving effective antibiotic levels in the fetal bloodstream
during labor. All three mechanisms attempt, ultimately, to decrease rates of neonatal sepsis,
pneumonia, and meningitis. This study examines the protective mechanism of achieving
effective antibiotic levels in the fetal bloodstream during labor by measuring fetal serum levels
of penicillin G. Due to natural variability in duration of labor, we cannot control duration of
prophylaxis in relation to the timing of umbilical cord blood sampling. This investigation is
therefore limited to observational study and cannot assess the impact of duration of prophylaxis
on rates of early onset group B streptococcal sepsis of the newborn. Furthermore, as was
discussed previously, this investigation used blood bank samples due to the difficulty of
obtaining consent during the rapidly progressing, less than four hour deliveries we were
interested in studying. The blood bank samples represent an underestimation of the penicillin G
levels contained in the cord blood at the time of delivery and not the actual levels at the time of
delivery.
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This study also did not evaluate the levels of penicillin G in the amniotic fluid, only in the
neonatal cord blood. Evaluating the amniotic fluid would have required performing an invasive
procedure, amniocentesis, in the setting of rapidly progressing deliveries or would have required
limiting our cohort to women undergoing Caesarian sections, which would have limited the
generalisability of our findings. As we did not examine the levels in the amniotic fluid, we are
unable to ascertain whether sufficiently high levels of penicillin G were obtained in the amniotic
fluid to prevent transmission via that route. However, in studies of ampicillin and cefazolin
when adequate concentrations were achieved in the cord blood, they were also reported in the
amniotic fluid.89, 96

The 4-hour time threshold recommended by the CDC is present throughout the literature on
intrapartum penicillin G chemoprophylaxis for group B streptococcus, but its origins are unclear.
A systematic review of published evidence suggests at best, that in women with established risk
factors for early-onset group B streptococcus disease of the newborn, greater than 1 or 2 hours of
intrapartum antibiotic prophylaxis is effective in reducing neonatal group B streptococcal
colonization or disease.48, 84, 97-99 Studies evaluating the current recommended penicillin G dosing
regimen in a cohort of maternal-fetal dyads have not been performed. We examined the duration
of maternal chemoprophylaxis necessary to achieve and maintain concentrations of penicillin G
above the minimum inhibitory concentration for group B streptococcus in fetal serum. As can
been seen from the demographic table [Table 1], our patient population is racially diverse,
represents both private and hospital clinic patients and patients cared for by both midwives and
physicians. Maternal age and gestational age were also varied. This patient population is
representative of a reproductive aged cohort of women at a large urban academic medical center.
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Even with the most valiant of efforts, there will frequently be group B streptococcus positive
mothers who arrive at the labor floor and deliver in less than four hours. Obstetric providers
have little control over the time patients arrive at the hospital to begin prophylaxis and likewise
little control over the progression of labor and the ultimate timing of delivery. Providers may
believe that four hours of prophylaxis are necessary to achieve adequate levels in the fetal
bloodstream to prevent group B streptococcus transmission and therefore, may choose not to
begin penicillin G dosing during precipitous labor. Our data indicates that fetal serum levels far
exceed the minimum inhibitory concentration at durations well under one hour, suggesting that
antibiotic prophylaxis should be pursued even in the most precipitous of deliveries.

The declining levels of penicillin G levels in the six patients who failed to receive the protocol
recommended 2.5 million units at the four-hour time point supports the four-hour dosing interval
recommended by the CDC. Additionally, patients who received 6 additional doses of 2.5 million
units had similar levels to those who received two additional doses. Fetal serum penicillin G
levels do not build with time, rather they return very close to baseline at the end of each fourhour interval. Therefore, adherence to dosing every four hours, independent of the duration of
the intrapartum prophylaxis should be a priority.

Knowledge about the dosing regimen has implications beyond the labor and delivery floor.
Preliminary studies as well as data from a large health maintenance organization demonstrated
that 40-50% of group B streptococcus colonized women do not receive antibiotics at least 4
hours prior to delivery due the rapidity of their labors.23, 100 More recent data from this year from
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the Active Bacterial Core Surveillance, a 10-state population based system which monitors group
B streptococcal disease, reported that in their group of patients 25% did not receive antibiotics
four hours prior to delivery.23 This effect is especially notable for multiparous women.
According to the 2002 CDC guidelines, the newborns of all group B streptococcus positive
women who present to labor units and deliver prior to 4 hours of intrapartum antibiotic
prophylaxis are deemed as „at risk‟ and recommended to undergo blood cultures, complete blood
count, and 48 hours of observation.9 At some institutions, these infants have been placed in
designated observation units for up to 6 hours after delivery to monitor for signs of sepsis, often
causing great angst for parents and care providers.

These interventions have not been proven to

reduce or detect more cases of group B streptococcal sepsis.101 Knowledge that fetal serum
penicillin G levels are far above the minimum inhibitory concentration within one hour raise the
possibility that these interventions and testing may be at best, superfluous, and at worst,
expensive and deleterious.

This study shows that fetal serum penicillin G levels far exceed the minimum inhibitory
concentration even for short durations of maternal intrapartum prophylaxis. However,
studies which correlate duration of prophylaxis with the clinical outcomes of early onset
group B streptococcal sepsis are needed before clinical practice can change. Much of the
current literature has examined neonatal group B streptococcal colonization, but the
utility of using this as a surrogate for risk of early onset group B streptococcal sepsis does
not have much, if any, supporting evidence. Therefore, studies investigating the duration
of prophylaxis in relation to incidence of early onset group B streptococcal sepsis are
necessary. If those studies are in line with the evidence presented here, the results may
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alter group B streptococcal sepsis protocols, so that in appropriate circumstances, shorter
durations of intrapartum prophylaxis may be considered adequate.

National agencies of health are charged with promoting the public health and welfare and
therefore have enormous responsibility to create guidelines and recommendations for
hospitals and health care providers to reduce the disease burden within our population.
Early-onset neonatal group B streptococcal disease has become largely preventable with
antenatal group B streptococcus screening among pregnant women and the use of
intrapartum antibiotic prophylaxis.102 Therefore, it is very appropriate that the CDC has
issued guidelines on this topic. The variations in the interpretation and application of
guidelines are often hard to anticipate. The recommendation to perform additional
testing and prolonged observation of newborns who have been exposed to less than four
hours of intrapartum prophylaxis has led many maternity care providers to attempt to
either prolong the duration of labor or avoid common interventions to hasten labor, in the
belief that four hours of intrapartum antibiotic exposure is preferable to a shorter labor
and a shorter duration of fetal exposure to the maternal organism. This is not an
irrational conclusion, especially if we assume that the evidence to support special
attention to infants born to group B streptococcus positive mothers after short labors is
well justified. However, if this evidence is not compelling or of high quality, prolonging
labor and fetal exposure to the organism may be neither in the best interest of the neonate
nor the mother.
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In the past several years, we have learned that the evidence supporting the four hour
threshold is weak, especially for low risk group B streptococcus positive women.45 These
would include those who are delivering at term, are afebrile, have no history of group B
streptococcus bacteriuria, have intact chorioamniotic membranes upon arrival, and have
no prior history of a group B streptococcus septic infant.16 Studies regarding the duration
of prophylaxis among these women and their newborns are lacking; however, low risk
women make up more than 90% of parturients exposed to the intrapartum prophylaxis
protocol.49 Among group B streptococcus positive women with risk factors, the existing
evidence supports at least one or two hours of intrapartum prophylaxis to significantly
reduce neonatal group B streptococcal colonization or disease.45 Maternal rectovaginal
group B streptococcal colonization declines rapidly within two to four hours of initiating
intrapartum prophylaxis87, while pharmacokinetic data shows that fetal penicillin G levels
peak within the first hour after maternal intravenous administration and remain 10-79fold greater than the minimum inhibitory concentration throughout the remainder of the
four hour interval.103 We are not aware of evidence to support attempts to prolong labor
in group B streptococcus positive women in order to reduce the risk of early onset
neonatal group B streptococcal sepsis. It is quite possible that efforts to prolong labor in
such women would actually increase the risk of sepsis in newborns. Indeed, the CDC
guidelines outline management for newborns that happen to deliver before four hours
have passed; the guidelines do not recommend altering the course of labor to achieve a
four-hour threshold. However, the confusion is understandable if providers assume that
an intrapartum antibiotic duration of four hours is strongly evidence-based.
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Our survey documents that on the labor floor at our academic medical center, the 2002
CDC guidelines on prevention of perinatal group B streptococcal disease had altering
effects on management of labor. The 2002 CDC document9 provides a flowchart
approach to the management of neonates born to mothers with group B streptococcal
colonization which indicates that maternal–infant dyads exposed to greater than four
hours of intrapartum antibiotic prophylaxis are considered adequately treated. In our
survey, respondent clinicians placed great emphasis on duration of prophylaxis and
attainment of four hours. Only 21.4% of clinicians stated that there would be no
difference in their instruction about time of admission between the group B streptococcus
positive and negative women. Once in labor, a majority of clinicians also indicated that
they would manage the labor course of group B streptococcus positive women differently
if they had not yet received four hours of prophylaxis with only 22.9% of clinicians
replying that they would make no changes to prolong the course of labor for these
women. Interventions included delaying rupture of membranes, stopping oxytocin
infusions, or instructing women to delay pushing or “labor down”. These alterations may
or may not negatively impact labor. Delaying rupture of membranes could have
theoretical benefit if the clinician is concerned about exposure of the fetus to the
colonized birth canal or ascending group B streptococcus infection in a slowly
progressing labor. However, stopping oxytocin infusions and “laboring down” carry the
risk that the fetus may spend a longer duration in the birth canal, increasing exposure to
the organism. Clinicians also reported increased stress resulting from the protocol for
patients, providers, hospital staff and patient families.

55
According to data published in 2009, women who were positive for group B
streptococcus were less likely to receive any intrapartum antibiotics when they presented
to the labor floor less than four hours before delivery when compared with those women
who presented greater than four hours before delivery.23 Anecdotally, we have heard
many staff on labor floors who believe that if a woman does not receive four hours of
antibiotics she is untreated and so there is no purpose in beginning antibiotic prophylaxis
if delivery is imminent. Under this interpretation of the 2002 guidelines, no antibiotic is
equal to 2 hours which is equal to 3 hours. From the data reviewed in this paper, this is
clearly not a valid interpretation of the literature. The institution of a four hour cutoff
may have the unintended impact of preventing women who would benefit from a short
duration of antibiotics from receiving any antibiotics at all.

Using a survey-based instrument to study provider practice patterns clearly has
limitations, because it depends on clinician report, which may not always mirror actual
practice. Documenting and comparing durations of labor and obstetric interventions
among group B streptococcus positive and negative women would be another means to
investigate provider practice patterns; however, it would not yield information about how
providers are interpreting the CDC guidelines and how they are applying the information
to different clinical scenarios. Our goal was to elucidate the latter, and therefore we
chose a survey-based approach. Another potential limitation of this study is that Yale
respondents may not necessarily be representative of clinicians at other medical centers,
because this center has a particular interest in this topic. Other medical center surveys
would be of interest.
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The 2002 Prevention of Perinatal Group B Streptococcal Disease guidelines from the
CDC provide an interesting case study on how guidelines can be interpreted differently in
the clinical setting than how might have been intended by the authors. This hospitalbased survey reveals that a majority of clinicians have altered their management of labor
among group B streptococcus positive women based on guidelines about managing
newborns after delivery exposed to different durations of intrapartum prophylaxis.
Further studies will be needed to enhance the evidence around optimal duration of
intrapartum prophylaxis, so that we can determine if prolonging labor to achieve this
threshold is actually more beneficial than delivering the infant in an expedited or
naturally timed fashion. Furthermore, additional testing and prolonged observation of
infants born to group B streptococcus positive mothers without other risk factors should
be more evidence-based given the unexpected repercussions that it has had on clinical
practice and patient and provider anxiety.
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